Does PTCY increase the risk of infections?

M Mikulska, C Bartalucci, AM Raiola, C Oltolini - Blood Reviews, 2023 - Elsevier
PTCY has been mainly used in haploidentical transplant (haploHSCT), but its use in
matched donors allowed better evaluation of infectious risk conferred separately by PTCY or …

CMV infection and CMV-specific immune reconstitution following haploidentical stem cell transplantation: an update

XH Luo, Y Zhu, YT Chen, LP Shui, L Liu - Frontiers in Immunology, 2021 - frontiersin.org
Haploidentical stem cell transplantation (haploSCT) has advanced to a common procedure
for treating patients with hematological malignancies and immunodeficiency diseases …

Low-dose post-transplant cyclophosphamide and anti-thymocyte globulin as an effective strategy for GVHD prevention in haploidentical patients

Y Wang, DP Wu, QF Liu, LP Xu, KY Liu… - Journal of hematology & …, 2019 - Springer
Background Low-dose post-transplant cyclophosphamide (PTCy) in conjunction with anti-
thymocyte globulin (ATG) appears as a potentially effective graft-versus-host disease …

Clinical “real‐world” experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients

A Anderson, M Raja, N Vazquez, M Morris… - Clinical …, 2020 - Wiley Online Library
Background Letermovir was approved in 2017 for prevention of cytomegalovirus (CMV)
infection in seropositive (R+) allogeneic hematopoietic cell transplantation (HCT) patients …

Reduced‐dose post‐transplant cyclophosphamide plus low‐dose post‐transplant anti‐thymocyte globulin as graft‐versus‐host disease prophylaxis with fludarabine …

W Zhang, R Gui, Y Zu, B Zhang, Z Li… - British Journal of …, 2023 - Wiley Online Library
Anti‐thymocyte globulin (ATG) or post‐transplant cyclophosphamide (PTCy)‐based
regimens are widely used for graft‐versus‐host disease (GVHD) prophylaxis in …

[HTML][HTML] Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post …

A Lin, J Flynn, L DeRespiris, B Figgins, M Griffin… - … and cellular therapy, 2021 - Elsevier
Cytomegalovirus (CMV) is serious viral infection in allogeneic hematopoietic cell
transplantation (allo-HCT) recipients. November 2017, the novel CMV DNA terminase …

Dual T-cell depletion with ATG and PTCy for peripheral blood reduced intensity conditioning allo-HSCT results in very low rates of GVHD

MQ Salas, S Prem, EG Atenafu, A Datt Law… - Bone Marrow …, 2020 - nature.com
The efficacy of posttransplant cyclophosphamide (PTCy) and antithymocyte globulin (ATG)
in controlling GVHD has been previously reported. We aim to study the safety and efficacy of …

[HTML][HTML] Impact of the addition of antithymocyte globulin to post-transplantation cyclophosphamide in haploidentical transplantation with peripheral blood compared to …

G Battipaglia, M Labopin, D Blaise… - … and Cellular Therapy, 2022 - Elsevier
The use of haploidentical hematopoietic cell transplantation (haplo-HCT) with peripheral
blood stem cells (PBSCs) to treat acute myelogenous leukemia (AML) is increasing. We …

Bone marrow versus mobilized peripheral blood stem cell graft in T-cell-replete haploidentical transplantation in acute lymphoblastic leukemia

A Nagler, B Dholaria, M Labopin, BN Savani… - Leukemia, 2020 - nature.com
The ideal stem cell graft source remains unknown in haploidentical haematopietic cell
transplantation (haplo-HCT) with posttransplantation cyclophosphamide (PTCy). This study …

Modified combination of anti-thymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) as compared with standard ATG protocol in haploidentical …

M Barkhordar, A Kasaeian, G Janbabai… - Frontiers in …, 2022 - frontiersin.org
In haploidentical peripheral blood stem cell transplantation (haplo-PBSCT), the combination
of anti-thymocyte globulin and post-transplant cyclophosphamide (ATG/PTCy) has a …